No Country for Old Organs

What are engineered organs and why are scientists trying to build them? Engineered organs are tissues grown or fabricated using stem cells, biomaterials, and advanced biofabrication technologies such as 3D bioprinting. As aging populations increase demand for organ transplants far beyond available donors, researchers are exploring whether organs could eventually be manufactured rather than donated.  

Modern organ transplantation is one of the most remarkable achievements of contemporary medicine. Since the first successful kidney transplant in 1954, overall transplant numbers have steadily increased; in the U.S. alone, more than 48,000 solid organs were transplanted in 2023, a record high. Yet over 100,000 people remain on waiting lists, with about 17 patients dying each day while waiting for a viable organ. As populations age across developed economies, the incidence of organ failure—from kidney disease to heart failure—is rising steadily, further widening the gap between available organs and patients who need them.

Yet this success story is constrained by scarcity. Organ donation remains limited by biology and logistics. Most transplantable organs are recovered only after death or through living donation of kidneys or liver segments, and compatibility filters such as blood type and tissue matching further restrict access. Once recovered, organs remain viable for only hours outside the body, meaning many potentially life-saving grafts go unused due to transportation delays. Even with advances like normothermic perfusion extending preservation times, geographic inequities and infrastructure gaps persist.

For recipients, transplantation is not a cure but a compromise. Lifelong immunosuppressive drugs are required to prevent rejection, significantly increasing the risk of infection and cancer. For example, organ transplant recipients have a multiple-fold increased cancer risk compared with age-matched controls. Treating organ failure in this way often substitutes one chronic health burden for another.

A Regenerative Paradigm Shift

Tissue engineering and related regenerative technologies aim to go beyond transplantation by producing replacement organs and tissues rather than waiting for donors. In effect, regenerative medicine attempts to reframe organ replacement as an engineering challenge: instead of relying on unpredictable donation pipelines, organs could eventually be fabricated using cells, biomaterials, and advanced biofabrication platforms.

This shift is reflected in a rapidly growing biotechnology industry. A 2024 industry analysis estimates over 700 companies worldwide developing regenerative therapies, including cell therapies, engineered tissues, and synthetic biomaterials. Another report from BioSpace valued the 3D bioprinting market at $2.58 billion in 2024 and projected it to increase to $8.42 billion by 2034, with an annual growth rate of 12.54%.

Key players in this emerging ecosystem span from startups pushing bioprinted organs toward clinical reality to companies delivering enabling tools for tissue construction and modeling.

3D Bioprinting and Engine Platforms

Organovo Holdings, Inc. — Founded in 2007 in San Diego, Organovo is among the earliest companies dedicated to 3D bioprinting of human tissues. Its technology produces engineered tissues for pharmaceutical research and, in the long term, therapeutic use. Organovo famously printed liver and kidney tissues in preclinical studies, and its bioprinted constructs are used for disease modeling and drug testing.

BICO Group — Based in Sweden, BICO supplies bioprinters, standardized bioinks, and related tools that enable tissue engineers to build complex tissues. Its platforms are used by academic and industrial researchers worldwide to grow cell-laden architectures — a foundational step toward future organ fabrication.

Aspect Biosystems — A Canadian biotech developing bioprinted therapeutic tissues. Aspect’s platform integrates cells, biomaterials, and computational design to print tissue constructs intended to repair or replace damaged organs, including work toward insulin-producing tissues for diabetes. The company recently expanded a partnership with pharmaceutical company Novo Nordisk to advance cell-based therapies with engineered tissues.

Frontier Bio Corporation — Focused on lab-grown lung tissue using combined 3D bioprinting and stem cell assemblies, with an eye toward both transplantable tissue and improved models for respiratory disease research.

Enabling Tools and Regenerative Platforms

Emulate, Inc. — Specializes in organs-on-chips technology, miniaturized microphysiological systems that replicate organ function for drug testing and disease modeling. While not transplant technologies per se, these tools accelerate research into human tissue behavior and reduce failure rates in clinical translation.

Integra LifeSciences and Stryker — Established medtech companies with regenerative divisions producing biologic scaffolds and engineered tissue products that assist wound healing, cartilage repair, and surgical reconstruction — foundational technologies that inform larger organ fabrication efforts.

Emerging and Enabling Startups

Beyond high-profile names, dozens of startups are pushing the technology frontier.

VivoTex — A new U.S. startup producing microfiber scaffolds to support microtissue and organoid assembly for regenerative medicine.

Tolemy Bio — A UK startup leveraging advanced media and metabolic profiling to support complex cell therapies and engineered tissues.

Academic spinoffs such as TissueTinker are even using bioprinting to model tumors, advancing both research and personalized approaches to therapy.

Together, companies across this landscape illustrate a broad surge in biofabrication technologies — from tools that support organoid growth and vascular network modeling to platforms aimed at constructing perfusable tissues at scale.

Engineering Complexity at Organ Scale

One of the largest scientific hurdles remains generating tissues with functional vasculature — without which implants cannot survive once scaled beyond thin layers. Research at academic and industry intersections is addressing this through innovations in synthetic vascular networks, advanced biomaterials, and real-time fabrication monitoring systems.

Public and private research initiatives — including U.S. government programs targeting bioprinting of kidneys, hearts, and livers — underscore how tissue fabrication is transitioning from theory to strategic national priority.

Why It Matters

If regenerative platforms mature to the point of producing patient-specific organs — grown from a person’s own cells — the implications are significant.

•  Reduced need for lifelong immunosuppression

•  Lower long-term costs compared with chronic care for organ failure

•  The potential for controlled “manufacturing” of organs rather than dependency on unpredictable donation pipelines

If successful, regenerative medicine could fundamentally change how healthcare systems treat organ failure, transforming transplantation from a scarce medical resource into a scalable biological technology. In that sense, the future of organ replacement may depend less on finding donors and more on building the biological infrastructure capable of manufacturing organs themselves.

However, ethical and economic questions about access, regulation, and cost will ultimately shape how these technologies benefit society.